Chimerix (CMRX) to Release Quarterly Earnings on Thursday

Chimerix (NASDAQ:CMRX) will issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, meeting the consensus estimate of ($0.23). The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $1.26 million. During the same period last year, the business earned ($0.21) EPS. On average, analysts expect Chimerix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chimerix Trading Up 6.1 %

CMRX traded up $0.06 during trading on Tuesday, hitting $1.05. 158,145 shares of the company’s stock traded hands, compared to its average volume of 351,777. The stock has a market capitalization of $94.12 million, a price-to-earnings ratio of -1.04 and a beta of 1.13. The company’s 50 day simple moving average is $0.90 and its two-hundred day simple moving average is $0.91. Chimerix has a 12-month low of $0.75 and a 12-month high of $1.30.

Analysts Set New Price Targets

CMRX has been the subject of several research analyst reports. Wedbush reiterated an “outperform” rating and issued a $6.00 price objective on shares of Chimerix in a report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Chimerix in a report on Wednesday, August 14th. Finally, StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research report on Wednesday, August 21st.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.